The Munn Lab
David Munn, MD
Interim Director, Georgia Cancer Center
Professor, Pediatric Oncology
Co-Director, Pediatric Immunotherapy Program
Medical College of Georgia
Augusta University
Jump to: Research SummaryImpact on Georgia patientsResearch Focus Research Interests Publications Team
Contact Us
The David Munn Lab
Health Sciences Campus
GCC - M. Bert Storey Research Building
1410 Laney Walker Blvd., CN-4156B3
(706) 721-7141
(706) 721-4804
Research Summary
Our research is focused on activating the body’s own immune system to fight cancer. We work on discovering the ways in which cancers suppress the immune system, and on identifying the molecular mechanisms that tumors use to escape from immune attack.
Along with our collaborators, we have developed new drugs and clinical strategies to activate the immune response against tumors and enlist the patients’ own immune system to enhance the effectiveness of conventional chemotherapy drugs and radiation. Target diseases include adult and pediatric solid tumors and brain tumors. Dr. Munn’s research is funded by the National Institutes of Health and support from charitable foundation donors.
Impact on Patients in Georgia
Our goal is to develop drugs that activate the body’s own immune system to enhance the effectiveness of standard chemotherapy and radiation treatments.
Results from our clinical trials are revealing that when the immune system is activated by the right kind of immunotherapy, then conventional chemotherapy and radiation can be used at modest, well-tolerated doses, and still achieve effectiveness better than either approach by itself.
The goal is to develop low-toxicity, well-tolerated outpatient regimens that do not require hospitalization, and provide patients with a good quality of life and return to activities such as school and work. Our clinical trials focus mainly on relapsed childhood brain tumors because the need for new treatments is so great in these children. But the same approaches can be applied to other childhood malignancies, and to adult tumors as well, so the potential impact is wide-ranging.
Research Focus
Our research focuses on tumor immunology and the molecular mechanisms of immune suppression and tolerance in the tumor microenvironment. The laboratory studies the regulation of anti-tumor T cell activation by tolerogenic dendritic cells and regulatory T cells (Tregs) in the setting of cancer.
Major focus areas in the laboratory include:
Research Interests
Immune Regulation & Tumor Tolerance
Basic-science studies of the indoleamine 2,3-dioxygenase (IDO) pathway in Tregs, including regulation of suppressor phenotype and reprogramming during inflammation. We also study how IDO-activated Tregs suppress immunogenic dendritic cells and support the development of small-molecule therapies.
Therapy-Induced Anti-Tumor Immunity
Basic and pre-clinical studies of immune response to dying tumor cells after chemotherapy; and synergy between conventional chemotherapy and novel forms of immunotherapy targeting Tregs and DCs.
Clinical Trials & Immune Monitoring
Design and immune-monitoring of Phase I and Phase II clinical trials of IDO-inhibitor drugs in combination with chemotherapy, radiation, BTK-inhibitor drugs and checkpoint inhibitors. These include first-in-children pediatric trials, in conjunction with the Pediatric Immunotherapy Service and Dr. Theodore Johnson.
View Pure Research Profile
| Publication |
|---|
Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33Lamorte, S., Quevedo, R., Jin, R., Neufeld, L., Liu, Z. Q., Ciudad, M. T., Lukhele, S., Bruce, J., Mishra, S., Zhang, X., Saeed, Z. K., Berman, H., Philpott, D. J., Girardin, S. E., Harding, S., Munn, D. H., Mak, T. W., Karlsson, M. C. I., Brooks, D. G. & McGaha, T. L., May 12 2025, In: Cancer Cell. 43, 5, p. 955-969.e10Research output: Contribution to journal › Article › peer-review |
β-blocker suppresses both tumoral sympathetic neurons and perivascular macrophages during oncolytic herpes virotherapyKyritsi, K., Pacholczyk, R., Douglass, E., Yu, M., Fang, H., Zhou, G., Kaur, B., Wang, Q., Munn, D. H. & Hong, B., Apr 5 2025, In: Journal for ImmunoTherapy of Cancer. 13, 4, e011322.Research output: Contribution to journal › Article › peer-review |
UFL1 promotes survival and function of virtual memory CD8 T cellsBhatt, B., Kumar, K., Shi, H., Ganesan, D., Anazodo, F., Rathakrishnan, A., Zhu, H., Wanna, A., Jiang, C., Jayavelu, T., Lokeshwar, V. B., Pacholczyk, R., Munn, D. H., Sheridan, B. S., Moskophidis, D., Li, H. & Singh, N., Mar 1 2025, In: Journal of immunology (Baltimore, Md. : 1950). 214, 3, p. 446-459 14 p.Research output: Contribution to journal › Article › peer-review |
Blocking Feedback Immunosuppression of Antigen Presentation in Brain Tumor During Oncolytic Virotherapy with oHSV-mshPKRTsuboi, N., Rivera-Caraballo, K. A., Sahu, U., Pacholczyk, R., Douglass, E., Johnson, T. S., Wang, Q., Kolhe, R., Hedrick, C. C., Munn, D. H. & Hong, B., Mar 1 2025, In: Molecular cancer therapeutics. 24, 3, p. 444-452 9 p.Research output: Contribution to journal › Article › peer-review |
Brain CD73 modulates interferon signaling to regulate glioblastoma invasionKyritsi, K., Ye, J., Douglass, E., Pacholczyk, R., Tsuboi, N., Otani, Y., Wang, Q., Munn, D. H., Kaur, B. & Hong, B., Jan 1 2025, In: Neuro-Oncology Advances. 7, 1, vdaf080.Research output: Contribution to journal › Article › peer-review |
Effect of indoximod-based chemo-immunotherapy in patients with pediatric brain tumors on activation and clonal proliferation of a circulating population of early non-exhausted stem-like CD8+ T cells whose on-treatment expansion is predictive of long-term outcome.Pacholczyk, R., Satpathy, S., Berrong, Z., Chien, F., Huang, C., Sadek, R. F., Thomas, B. E., Smith, C., MacDonald, T. J., Kennedy, E. P., Johnson, T. S., Bhasin, M. K. & Munn, D. H., Jun 2024, In: Journal of Clinical Oncology. 42, p. 2566 1 p.Research output: Contribution to journal › Review article › peer-review |
Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trialJohnson, T. S., MacDonald, T. J., Pacholczyk, R., Aguilera, D., Al-Basheer, A., Bajaj, M., Bandopadhayay, P., Berrong, Z., Bouffet, E., Castellino, R. C., Dorris, K., Eaton, B. R., Esiashvili, N., Fangusaro, J. R., Foreman, N., Fridlyand, D., Giller, C., Heger, I. M., Huang, C. & Kadom, N. & 18 others, , Feb 1 2024, In: Neuro-Oncology. 26, 2, p. 348-361 14 p.Research output: Contribution to journal › Article › peer-review |
Enniatin A inhibits the chaperone Hsp90 and unleashes the immune system against triple-negative breast cancerEisa, N. H., Crowley, V. M., Elahi, A., Kommalapati, V. K., Serwetnyk, M. A., Llbiyi, T., Lu, S., Kainth, K., Jilani, Y., Marasco, D., El Andaloussi, A., Lee, S., Tsai, F. T. F., Rodriguez, P. C., Munn, D., Celis, E., Korkaya, H., Debbab, A., Blagg, B. & Chadli, A., Dec 15 2023, In: iScience. 26, 12, 108308.Research output: Contribution to journal › Article › peer-review |
Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitmentKlement, J. D., Redd, P. S., Lu, C., Merting, A. D., Poschel, D. B., Yang, D., Savage, N. M., Zhou, G., Munn, D. H., Fallon, P. G. & Liu, K., Mar 13 2023, In: Cancer Cell. 41, 3, p. 620-636.e9Research output: Contribution to journal › Article › peer-review |
The Simple prEservatioN of Single cElls method for cryopreservation enables the generation of single-cell immune profiles from whole bloodSatpathy, S., Thomas, B. E., Pilcher, W. J., Bakhtiari, M., Ponder, L. A., Pacholczyk, R., Prahalad, S., Bhasin, S. S., Munn, D. H. & Bhasin, M. K., 2023, In: Frontiers in immunology. 14, 1271800.Research output: Contribution to journal › Article › peer-review |
Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responsesMandula, J. K., Chang, S., Mohamed, E., Jimenez, R., Sierra-Mondragon, R. A., Chang, D. C., Obermayer, A. N., Moran-Segura, C. M., Das, S., Vazquez-Martinez, J. A., Prieto, K., Chen, A., Smalley, K. S. M., Czerniecki, B., Forsyth, P., Koya, R. C., Ruffell, B., Cubillos-Ruiz, J. R., Munn, D. H. & Shaw, T. I. & 2 others, , Oct 10 2022, In: Cancer Cell. 40, 10, p. 1145-1160.e9Research output: Contribution to journal › Article › peer-review |
Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapyAboelella, N. S., Brandle, C., Okoko, O., Gazi, M. Y., Ding, Z. C., Xu, H., Gorman, G., Bollag, R., Davila, M. L., Bryan, L. J., Munn, D. H., Piazza, G. A. & Zhou, G., Jul 26 2022, In: Journal for ImmunoTherapy of Cancer. 10, 7, e004938.Research output: Contribution to journal › Article › peer-review |
Retinoic acid signaling acts as a rheostat to balance Treg functionThangavelu, G., Andrejeva, G., Bolivar-Wagers, S., Jin, S., Zaiken, M. C., Loschi, M., Aguilar, E. G., Furlan, S. N., Brown, C. C., Lee, Y. C., Hyman, C. M. D., Feser, C. J., Panoskaltsis-Mortari, A., Hippen, K. L., MacDonald, K. P., Murphy, W. J., Maillard, I., Hill, G. R., Munn, D. H. & Zeiser, R. & 5 others, , Jul 2022, In: Cellular and Molecular Immunology. 19, 7, p. 820-833 14 p.Research output: Contribution to journal › Article › peer-review |
BET-bromodomain and EZH2 inhibitor–treated chronic GVHD mice have blunted germinal centers with distinct transcriptomesZaiken, M. C., Flynn, R., Paz, K. G., Rhee, S. Y., Jin, S., Mohamed, F. A., Saha, A., Thangavelu, G., Park, P. M. C., Hemming, M. L., Sage, P. T., Sharpe, A. H., DuPage, M., Bluestone, J. A., Panoskaltsis-Mortari, A., Cutler, C. S., Koreth, J., Antin, J. H., Soiffer, R. J. & Ritz, J. & 12 others, , May 12 2022, In: Blood. 139, 19, p. 2983-2997 15 p.Research output: Contribution to journal › Article › peer-review |
Immunosuppressive metabolites in tumoral immune evasion: Redundancies, clinical efforts, and pathways forwardJennings, M. R., Munn, D. & Blazeck, J., Oct 19 2021, In: Journal for ImmunoTherapy of Cancer. 9, 10, e003013.Research output: Contribution to journal › Review article › peer-review |
Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunitySharma, M. D., Pacholczyk, R., Shi, H., Berrong, Z. J., Zakharia, Y., Greco, A., Chang, C. S. S., Eathiraj, S., Kennedy, E., Cash, T., Bollag, R., RAVINDRA, K., Sadek, R., McGaha, T. L., Rodriguez, P., Mandula, J., Blazar, B. R., Johnson, T. S. & Munn, D. H., Oct 12 2021, In: Immunity. 54, 10, p. 2354-2371.e8Research output: Contribution to journal › Article › peer-review |
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanomaZakharia, Y., McWilliams, R. R., Rixe, O., Drabick, J., Shaheen, M. F., Grossmann, K. F., Kolhe, R., Pacholczyk, R., Sadek, R., Tennant, L. L., Smith, C. M., Kennedy, E. P., Link, C. J., Vahanian, N. N., Yu, J., Shen, S. S., Brincks, E. L., Rossi, G. R., Munn, D. & Milhem, M., Jun 11 2021, In: Journal for ImmunoTherapy of Cancer. 9, 6, e002057.Research output: Contribution to journal › Article › peer-review |
Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responsesThangavelu, G., Wang, C., Loschi, M., Saha, A., Osborn, M. J., Furlan, S. N., Aoyama, K., McDonald-Hyman, C., Aguilar, E. G., Janesick, A. S., Chandraratna, R. A., Refaeli, Y., Panoskaltsis-Mortari, A., MacDonald, K. P., Hill, G. R., Zeiser, R., Maillard, I., Serody, J. S., Murphy, W. J. & Munn, D. H. & 7 others, , Feb 25 2021, In: Blood. 137, 8, p. 1090-1103 14 p.Research output: Contribution to journal › Article › peer-review |
CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpointYu, M., Guo, G., Huang, L., Deng, L., Chang, C. S., Achyut, B. R., Canning, M., Xu, N., Arbab, A. S., Bollag, R. J., Rodriguez, P. C., Mellor, A. L., Shi, H., Munn, D. H. & Cui, Y., Dec 1 2020, In: Nature communications. 11, 1, 515.Research output: Contribution to journal › Article › peer-review |
Persistent STAT5 activation reprograms the epigenetic landscape in CD4+ T cells to drive polyfunctionality and antitumor immunityDing, Z. C., Shi, H., Aboelella, N. S., Fesenkova, K., Park, E. J., Liu, Z., Pei, L., Li, J., McIndoe, R. A., Xu, H., Piazza, G. A., Blazar, B. R., Munn, D. H. & Zhou, G., Oct 30 2020, In: Science immunology. 5, 52, aba5962.Research output: Contribution to journal › Article › peer-review |
P50 suppresses cytotoxic T lymphocyte effector function to regulate tumor immune escape and response to immunotherapyLu, C., Klement, J. D., Smith, A. D., Yang, D., Waller, J. L., Browning, D. D., Munn, D. H. & Liu, K., Oct 13 2020, In: Journal for ImmunoTherapy of Cancer. 8, 2, 230.Research output: Contribution to journal › Article › peer-review |
Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with GlioblastomaLadomersky, E., Zhai, L., Lauing, K. L., Bell, A., Xu, J., Kocherginsky, M., Zhang, B., Wu, J. D., Podojil, J. R., Platanias, L. C., Mochizuki, A. Y., Prins, R. M., Kumthekar, P., Raizer, J. J., Dixit, K., Lukas, R. V., Horbinski, C., Wei, M., Zhou, C. & Pawelec, G. & 5 others, , Oct 1 2020, In: Clinical Cancer Research. 26, 19, p. 5232-5245 14 p.Research output: Contribution to journal › Article › peer-review |
The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING SignalingMohamed, E., Sierra, R. A., Trillo-Tinoco, J., Cao, Y., Innamarato, P., Payne, K. K., de Mingo Pulido, A., Mandula, J., Zhang, S., Thevenot, P., Biswas, S., Abdalla, S. K., Costich, T. L., Hänggi, K., Anadon, C. M., Flores, E. R., Haura, E. B., Mehrotra, S., Pilon-Thomas, S. & Ruffell, B. & 4 others, , Apr 14 2020, In: Immunity. 52, 4, p. 668-682.e7Research output: Contribution to journal › Article › peer-review |
Delayed Akt suppression in the lipopolysaccharide-induced acute lung injury promotes resolution that is associated with enhanced effector regulatory T cellsArtham, S., Verma, A., Alwhaibi, A., Adil, M. S., Manicassamy, S., Munn, D. H. & Somanath, P. R., Apr 2020, In: American Journal of Physiology - Lung Cellular and Molecular Physiology. 318, 4, p. L750-L761Research output: Contribution to journal › Article › peer-review |
Inhibition of inositol kinase B controls acute and chronic graft-versus-host diseaseThangavelu, G., Du, J., Paz, K. G., Loschi, M., Zaiken, M. C., Flynn, R., Taylor, P. A., Kirchmeier, A. K., Panoskaltsis-Mortari, A., Luznik, L., MacDonald, K. P., Hill, G. R., Maillard, I., Munn, D. H., Serody, J. S., Murphy, W. J., Miklos, D., Cutler, C. S., Koreth, J. & Antin, J. H. & 5 others, , 2020, In: Blood. 135, 1, p. 28-40 13 p.Research output: Contribution to journal › Article › peer-review |
ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repressionCao, Y., Trillo-Tinoco, J., Sierra, R. A., Anadon, C., Dai, W., Mohamed, E., Cen, L., Costich, T. L., Magliocco, A., Marchion, D., Klar, R., Michel, S., Jaschinski, F., Reich, R. R., Mehrotra, S., Cubillos-Ruiz, J. R., Munn, D. H., Conejo-Garcia, J. R. & Rodriguez, P. C., Dec 1 2019, In: Nature communications. 10, 1, 1280.Research output: Contribution to journal › Article › peer-review |
Publisher Correction: ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression (Nature Communications, (2019), 10, 1, (1280), 10.1038/s41467-019-09263-1)Cao, Y., Trillo-Tinoco, J., Sierra, R. A., Anadon, C., Dai, W., Mohamed, E., Cen, L., Costich, T. L., Magliocco, A., Marchion, D., Klar, R., Michel, S., Jaschinski, F., Reich, R. R., Mehrotra, S., Cubillos-Ruiz, J. R., Munn, D. H., Conejo-Garcia, J. R. & Rodriguez, P. C., Dec 1 2019, In: Nature communications. 10, 1, 3680.Research output: Contribution to journal › Comment/debate › peer-review |
GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironmentHalaby, M. J., Hezaveh, K., Lamorte, S., Ciudad, M. T., Kloetgen, A., MacLeod, B. L., Guo, M., Chakravarthy, A., Da Silva Medina, T., Ugel, S., Tsirigos, A., Bronte, V., Munn, D. H., Pugh, T. J., De Carvalho, D. D., Butler, M. O., Ohashi, P. S., Brooks, D. G. & McGaha, T. L., Dec 2019, In: Science immunology. 4, 42, eaax8189.Research output: Contribution to journal › Article › peer-review |
Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHDKoehn, B. H., Saha, A., McDonald-Hyman, C., Loschi, M., Thangavelu, G., Ma, L., Zaiken, M., Dysthe, J., Krepps, W., Panthera, J., Hippen, K., Jameson, S. C., Miller, J. S., Cooper, M. A., Farady, C. J., Iwawaki, T., Ting, J. P. Y., Serody, J. S., Murphy, W. J. & Hill, G. R. & 5 others, , Nov 7 2019, In: Blood. 134, 19, p. 1670-1682 13 p.Research output: Contribution to journal › Article › peer-review |
Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host diseasePaz, K., Flynn, R., Du, J., Tannheimer, S., Johnson, A. J., Dong, S., Stark, A. K., Okkenhaug, K., Panoskaltsis-Mortari, A., Sage, P. T., Sharpe, A. H., Luznik, L., Ritz, J., Soiffer, R. J., Cutler, C. S., Koreth, J., Antin, J. H., Miklos, D. B., MacDonald, K. P. & Hill, G. R. & 10 others, , Jun 2019, In: American Journal of Transplantation. 19, 6, p. 1820-1830 11 p.Research output: Contribution to journal › Article › peer-review |
Dendritic Cell Expression of Retinal Aldehyde Dehydrogenase-2 Controls Graft-versus-Host Disease LethalityThangavelu, G., Lee, Y. C., Loschi, M., Melanie Schaechter, K., Feser, C. J., Koehn, B. H., Nowak, E. C., Zeiser, R., Serody, J. S., Murphy, W. J., Munn, D. H., Chambon, P., Noelle, R. J. & Blazar, B. R., May 1 2019, In: Journal of Immunology. 202, 9, p. 2795-2805 11 p.Research output: Contribution to journal › Article › peer-review |
Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethalitySaha, A., Taylor, P. A., Lees, C. J., Panoskaltsis-Mortari, A., Osborn, M. J., Feser, C. J., Thangavelu, G., Melchinger, W., Refaeli, Y., Hill, G. R., Munn, D. H., Murphy, W. J., Serody, J. S., Maillard, I., Kreymborg, K., van den Brink, M., Dong, C., Huang, S., Zang, X. & Allison, J. P. & 2 others, , 2019, In: JCI Insight. 4, 19, e127716.Research output: Contribution to journal › Article › peer-review |
The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host diseaseMcDonald-Hyman, C., Muller, J. T., Loschi, M., Thangavelu, G., Saha, A., Kumari, S., Reichenbach, D. K., Smith, M. J., Zhang, G., Koehn, B. H., Lin, J., Mitchell, J. S., Fife, B. T., Panoskaltsis-Mortari, A., Feser, C. J., Kirchmeier, A. K., Osborn, M. J., Hippen, K. L., Kelekar, A. & Serody, J. S. & 6 others, , Oct 1 2018, In: Journal of Clinical Investigation. 128, 10, p. 4604-4621 18 p.Research output: Contribution to journal › Article › peer-review |
Treg Destabilization and reprogramming: Implications for cancer immunotherapyMunn, D. H., Sharma, M. D. & Johnson, T. S., Sep 15 2018, In: Cancer Research. 78, 18, p. 5191-5199 9 p.Research output: Contribution to journal › Review article › peer-review |
Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF-α-Dependent Intensification of Oxidative Stress and Tumor Cell DeathHabtetsion, T., Ding, Z.-C., Pi, W., Li, T., Lu, C., Chen, T., Xi, C., Spartz, H., Liu, K., Hao, Z., Mivechi, N. F., Huo, Y., Blazar, B. R., Munn, D. H. & Zhou, G., Aug 7 2018, In: Cell Metabolism. 28, 2, p. 228-242.e6Research output: Contribution to journal › Article › peer-review |
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumorsNayak-Kapoor, A., Hao, Z., Sadek, R., Dobbins, R., Marshall, L., Vahanian, N. N., Jay Ramsey, W., Kennedy, E., Mautino, M. R., Link, C. J., Lin, R. S., Royer-Joo, S., Liang, X., Salphati, L., Morrissey, K. M., Mahrus, S., McCall, B., Pirzkall, A., Munn, D. H. & Janik, J. E. & 1 others, , Jun 20 2018, In: Journal for ImmunoTherapy of Cancer. 6, 1, 61.Research output: Contribution to journal › Article › peer-review |
Apoptotic cell-induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans articleShinde, R., Hezaveh, K., Halaby, M. J., Kloetgen, A., Chakravarthy, A., Da Silva Medina, T., Deol, R., Manion, K. P., Baglaenko, Y., Eldh, M., Lamorte, S., Wallace, D., Chodisetti, S. B., Ravishankar, B., Liu, H., Chaudhary, K., Munn, D. H., Tsirigos, A., Madaio, M. & Gabrielsson, S. & 4 others, , Jun 1 2018, In: Nature Immunology. 19, 6, p. 571-582 12 p.Research output: Contribution to journal › Article › peer-review |
The host protecting the tumor from the host — targeting PD‑L1 expressed by host cellsMunn, D. H., Feb 1 2018, In: Journal of Clinical Investigation. 128, 2, p. 570-572 3 p.Research output: Contribution to journal › Review article › peer-review |
Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in TumorsSharma, M. D., Rodriguez, P. C., Koehn, B. H., Baban, B., Cui, Y., Guo, G., Shimoda, M., Pacholczyk, R., Shi, H., Lee, E. J., Xu, H., Johnson, T. S., He, Y., Mergoub, T., Venable, C., Bronte, V., Wolchok, J. D., Blazar, B. R. & Munn, D. H., Jan 16 2018, In: Immunity. 48, 1, p. 91-106.e6Research output: Contribution to journal › Article › peer-review |
In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus KynureninesHippen, K. L., O'Connor, R. S., Lemire, A. M., Saha, A., Hanse, E. A., Tennis, N. C., Merkel, S. C., Kelekar, A., Riley, J. L., Levine, B. L., June, C. H., Turka, L. A., Kean, L. S., MacMillan, M. L., Miller, J. S., Wagner, J. E., Munn, D. H. & Blazar, B. R., Dec 2017, In: American Journal of Transplantation. 17, 12, p. 3098-3113 16 p.Research output: Contribution to journal › Article › peer-review |
Research Team
